The case for & against
Bull & Bear analysis
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is an emerging biotechnology firm emphasizing artificial intelligence and advanced data analytics within the realm of drug discovery. Positioned as a leading AI-first drug discovery platform, Recursion combines extensive biological data generation with machine learning to accelerate the development of new therapeutics, particularly targeting oncology and rare diseases. The company utilizes proprietary technology, known as Recursion OS, to innovate drug development processes while collaborating with major pharmaceutical firms, underscoring its strategic importance within the dynamic biotech landscape.
Bull says
- ↑ARK Invest acquired 260k shares, reaffirming AI-driven pipeline appeal
- ↑Q1 2026 cash at $754M supports growth initiatives, runway to early 2028
- ↑REC-4881 proof-of-concept achieved 43% median polyp burden reduction
- ↑$500M in cumulative partner inflows validates platform; boosts non-dilutive funding
- ↑AI platform reduces compounds by 90% and cuts development to 17 months
- ↑Positive analyst revisions and strong liquidity underpin improved sentiment
Bear says
- ↓35.1% short interest indicates significant bearish conviction in fundamentals
- ↓Earnings yield of –1.9% and weak profitability raise sustainability concerns
- ↓Drug discovery faces ~90% failure rate, heightening clinical execution risk
- ↓Despite 35% expense cuts, high cash burn demands strict cost discipline
- ↓Reliance on partner milestone payments exposes cash flow to delays
- ↓Volatility elevated (score 4.6), signaling potential for extreme price swings
Investment themes with RXRX
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- So 2025 was a year of financial transformation for the company, as we were able to achieve the efficiencies that we did over the last year while still advancing a portfolio of five clinical programs, hitting multiple different partner milestones, really investing behind the growth in our platform as well.
- So we ended the year with $754 million in cash.
- Looking forward, our 2026 cash operating expenses are expected to be under $390 million, reflecting our commitment to maintaining a lean and efficient operating structure.
Bear points
- The current PI3K inhibitors have been constrained, and we have some data that we'll share shortly, hyperglycemia, metabolic toxicity, dose interruptions, dose reductions, limited treatment duration.
- current PI3K inhibitors focusing on HR-positive breast cancer do have tolerability limitations. 65% to 85% experience hyperglycemia. Large percent actually also have dose interruptions, dose reductions, some of those driven by the hyperglycemia they're experiencing.